公开(公告)号：US11590074B2

公开(公告)日：2023-02-28

申请号：US17019740

申请日：2020-09-14

申请人： CHIESI FARMACEUTICI S.p.A.

发明人： Sauro Bonelli ,  Francesca Usberti ,  Enrico Zambelli

IPC分类号： A61K9/00 ,  A61K31/167 ,  A61K31/40 ,  A61K31/573 ,  A61K45/06 ,  A61P11/00 ,  A61K47/06 ,  A61K47/10 ,  B65B31/06 ,  B65B31/10

摘要： Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

公开(公告)号：US20220331244A1

公开(公告)日：2022-10-20

申请号：US17763595

申请日：2020-09-22

申请人： Chiesi Farmaceutici S.p.A.

发明人： Tomaso GUIDI ,  Andrea BENASSI

IPC分类号： A61K9/00 ,  A61K47/26 ,  A61K31/573

摘要： The present invention concerns carrier particles for dry powder formulations for inhalation and a process for their preparation thereof.

公开(公告)号：US20220265559A1

公开(公告)日：2022-08-25

申请号：US17742960

申请日：2022-05-12

申请人： Chiesi Farmaceutici S.p.A.

发明人： Bernard Charles SHERMAN ,  Michael SPINO

IPC分类号： A61K9/28 ,  A61K9/20 ,  A61K31/4412 ,  A61K31/4422 ,  A61P7/06 ,  A61P25/28 ,  A61P35/00

摘要： The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

公开(公告)号：US11311691B2

公开(公告)日：2022-04-26

申请号：US15566908

申请日：2015-04-28

申请人： CHIESI FARMACEUTICI S.p.A

发明人： Raffaele Dellaca ,  Ilaria Milesi ,  Emanuela Zannin

IPC分类号： A61M16/04 ,  A61M16/08

摘要： A device (100) for facilitating the positioning of a catheter for the delivery of liquid medicament to spontaneously breathing patient, including: —an elongated main body (101) shaped to follow the internal shape of the patient's upper airways, the elongated main body (101) being provided with guiding means (107) adapted to house a catheter; —a substantially ring-shaped terminal element (103) adapted to engage the internal wall of the patient's retro-pharynx, the substantially ring-shaped terminal element (103) being connected to the elongated main body (101) by means of at least one spoke (105), the substantially ring-shaped element (103) and the at least one spoke (105) creating a chamber where the medicament can be delivered through the catheter.

公开(公告)号：US20220064243A1

公开(公告)日：2022-03-03

申请号：US17277240

申请日：2019-09-17

申请人： CHIESI FARMACEUTICI S.P.A.

发明人： Gino VILLETTI ,  Bruno Pietro IMBIMBO ,  Laura CALZÀ

IPC分类号： C07K14/48 ,  A61P17/02

摘要： The present invention provides a non-natural polypeptide for the treatment or prevention of skin disorders in a mammal. Administration of the polypeptide is well tolerated by the mammal. The non-natural polypeptide is provided at high purity.

公开(公告)号：US11260071B2

公开(公告)日：2022-03-01

申请号：US16609800

申请日：2018-06-22

申请人： Chiesi Farmaceutici S.p.A.

发明人： Thomas Diacovo

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7076 ,  A61P7/02 ,  A61K9/00

摘要： The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.

公开(公告)号：USD940860S1

公开(公告)日：2022-01-11

申请号：US29727564

申请日：2020-03-11

申请人： Chiesi Farmaceutici S.p.A.

设计人： Jurgen Pfrang ,  Andreas Gorshofer ,  Marta Lombardini

公开(公告)号：US11141422B2

公开(公告)日：2021-10-12

申请号：US16374989

申请日：2019-04-04

申请人： Chiesi Farmaceutici S.p.A.

发明人： David Kylhammar ,  Goran Radegran

IPC分类号： A61K31/7076 ,  A61K31/00 ,  A61K45/06 ,  A61K9/00 ,  E21B10/10 ,  E21B10/22 ,  E21D9/10

摘要： The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y12 receptor antagonist. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.

公开(公告)号：US20210290540A1

公开(公告)日：2021-09-23

申请号：US17262802

申请日：2019-07-24

申请人： CHIESI FARMACEUTICI S.p.A.

发明人： Tomaso GUIDI ,  Amrit PAUDEL ,  Sarah Elizabeth ZELLNITZ ,  Joana Filipa Fernandes TEIXEIRA PINTO

IPC分类号： A61K9/16 ,  A61K9/00

摘要： The present invention concerns carrier particles suitable for use in dry powder formulations for inhalation. The invention also relates to processes for their preparation by spray-congealing.

公开(公告)号：US11052202B2

公开(公告)日：2021-07-06

申请号：US14069755

申请日：2013-11-01

申请人： CHIESI FARMACEUTICI S.p.A.

发明人： Mark Parry-Billings ,  Mario Scuri ,  Maria Chiara Taverna

IPC分类号： A61M15/00 ,  A61M16/00 ,  G16H20/10

摘要： Drug delivery devices that include a microphone and processing circuitry that can detect operating events, such as peak inspiratory flow (PIF) and Breath Actuated Mechanism (BAM) in dry powder inhalers can be used to improve clinical trials by providing information about the way in which the inhalers under test are being used.